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ABSTRACT
Acute fatty liver of pregnancy (AFLP) is a rare catastrophic illness constituting an obstetric emergency in 
third trimester of pregnancy and may have complications for both mother and fetus, including death. Yet it is 
still unclear, the pathogenesis of AFLP has been identified related to defects in fatty acid metabolism during 
pregnancy, especially in the setting of fetal genetic defects in fatty oxidation. Establishing the diagnosis of AFLP 
is challenging, further it may overlap with other liver diseases of pregnancy, such as preeclampsia and hemolysis, 
elevated liver enzymes, low platelet count (HELLP) syndrome. The management of AFLP is a multidisciplinary 
progress providing the prompt intervention more than the termination of the pregnancy. The awareness of AFLP 
is highly needed to provide early diagnosis and management so that it can reduce the morbidity and mortality.
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ABSTRAK
Acute fatty liver of pregnancy (AFLP) merupakan penyakit yang jarang ditemukan namun memiliki gambaran 
klinis yang berat dan merupakan salah satu kegawatdaduratan dalam bidang obstretik ginekologi yang terjadi 
di trimester ketiga dan dapat menyebabkan komplikasi baik bagi ibu maupun janin yang bisa mengakibatkan 
kematian. Patogenesis terjadinya AFLP masih belum jelas, namun dikatakan hal ini terjadi terkait dengan defek 
yang berhubungan dengan  metabolisme asam lemak pada saat kehamilan, terutama defek terjadi secara genetik 
yang melibatkan proses oksidasi lemak. Menegakkan diagnosis AFLP merupakan tantangan karena dapat terjadi 
tumpang tindih dengan penyakit hati pada kehamilan lainnya, seperti preeklamsia dan hemolysis, elevated liver 
enzymes, and low platelet count (HELLP) syndrome. Penanganan dan tata laksana AFLP melibatkan berbagai 
macam disiplin ilmu karena terkait pula dengan masalah terminasi kehamilan dan intervensi lanjutan yang 
dapat diberikan kepada pasien. Kewaspadaan terhadap AFLP sejak dini dibutuhkan agar menurunkan angka 
morbiditas dan mortalitas. 
Kata kunci: acute fatty liver of pregnancy, diagnosis, tata laksana  
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INTRODUCTION
A 28 years old pregnant women brought to the 
emergency unit with altered mental status since 4 hours 
before admission. She seemed having difficulty in 
breathing. She was 34 months of her second pregnancy. 
No fever was reported. On her last antenatal care, the 
condition of pregnancy was normal for both mother 
and baby. The vital signs were Glasgow coma scale 
(GCS) 11, high blood pressure (190/130 mmHg), 
tachycardia, and tachypnea. Laboratory findings 
revealed elevated alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST), slightly increased 
bilirubin, slight prolongation of both prothrombin time 
(PT) and activated partial thromboplastin time (aPTT). 
She was diagnosed as acute fatty liver of pregnancy 
(AFLP). She was then intubated and underwent 
emergency cesarean delivery. She survived after 6 days 
ICU hospitalization and then she was discharged on 
the 9th day of hospitalization. Unfortunately, the baby 
did not survive. 
There are alterations of physiological and hormonal 
profiles during normal pregnancy, including liver 
biochemical profiles. Abnormality of the liver test 
during pregnancy occurs in 3-5% of pregnancies, 
which can caused by several condition.5 Liver 
disease in pregnancies is rarely happen, but it can 
still occur and can relates to high morbidity and 
mortality for both mother and the fetus.1,2,3 Liver 
disease in pregnancy can divided into 2 categories, 
one depending on their association with or without 
preeclampsia. The preeclampsia-related liver disorders 
include preeclampsia, HELLP syndrome, and AFLP. 
Hyperemesis gravidarum (HG) and intrahepatic 
cholestasis of pregnancy (ICP) were not  preeclampsia-
related liver disorders.3-5 
AFLP is a rare, but potentially fatal, complication 
of the third trimester of pregnancy (median gestation 
age is 36 weeks).1-4 It remains an obstetric emergency 
for both mother (20-30% mortality) and fetus (20-50% 
mortality).3 However, the need for early diagnosis and 
treatment is still the unmet crucial aspect.
EPIDEMIOLOGY
The AFLP is a relatively rare disease of pregnancy. 
The incidence of AFLP ranges between 1:7,000-
15,000.1,3 One study reported that the incidence of 
AFLP in Southeastern Wales was as high as 1:1,000.5 
Qiang G et al reported that the proportion of AFLP at 
four tertiary hospitals in China was 9.8%.6 Muhammad 
IAA et al showed that the incidence of AFLP at tertiary 
hospital in Indonesia was 2-3 patients per year.7 It 
affects woman in all ages during pregnancy and there 
is no evidence of distinctive epidemiologic feature 
related.2,8
Some risk factors for AFLP have been identified 
(Table 1). Multiple gestation are believed to be at 
greater risk because of increased fetal production 
of fatty acid metabolites by more than one fetus.9 It 
is unclear if other liver disease of pregnancy might 
predispose women to AFLP or are merely associated, 
but some studies showed the comorbidities. Studies 
showed that up to 20% women with AFLP may also be 
diagnosed with hemolysis, elevated liver enzymes, low 
platelets (HELLP) syndrome, which itself is associated 
with preeclampsia.10-11 Other study showed that there is 
association between AFLP and intrahepatic cholestasis 
of pregnancy (ICP).12
Table 1. Risk factors for AFLP
Nulliparity1, 3, 13-14
Co-existing of other liver disease of pregnancy (HELLP, 
preeclampsia)2, 13
Pregnancies with a male fetus2-3, 13
Previous episode of AFLP2
Multiple gestation3, 13-14
Low body mass index13, 15
HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty 
liver of pregnancy 
PHYSIOLOGICAL CHANGES DURING PREGNANCY
In normal pregnancy, physiological and hormonal 
changes occur within the human body, some of 
which can mimic those seen in women with liver 
disease. There is an increasing maternal heart rate, 
cardiac output rises by 40%, the circulating plasma 
volume increases by 30%, and peripheral vascular 
resistance is reduced. However, blood flow to the 
liver remains essentially unchanged (approximately 
25-33% of cardiac output) during pregnancy. Due to 
the enlarging uterus, the liver may be slightly elevated 
within the abdomen with increasing gestation.16-18 Gall 
bladder decreases its motility results in higher risk of 
developing gallstones.17-18 
Physiological changes in liver function tests 
during pregnancy must not be mistaken for liver 
dysfunction (Table 2). Liver enzymes including alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyl transferase (GGT), and 
bilirubin remain normal. Alkaline phosphatase (ALP) 
increases with advancing gestation as a result of 
placental production and fetal bone development, 
and high level should not be considered abnormal. 
The alpha fetoprotein (AFP) level increases as AFP 
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is produced by the fetal liver. Total protein decreases 
during pregnancy, primarily because of a decreased 
in albumin. Increased estrogen causes an increase in 
fibrinogen and other clotting factors (factor VII, VIII, 
IX, and X), so called pro-coagulant state.3, 16-18 
Table 2. Physiological changes in liver function tests during 
normal pregnancy3, 19
Test Normal range
Bilirubin Not change or slightly decrease
ALT Not change
AST Not change
Prothrombin time Not change
Alkaline phosphatase Increase 2 to 4-fold
Fibrinogen Increase 50%
Globulin Increase in alpha & beta globulins, 
decrease in gamma globulin
Alpha-fetoprotein Moderate increase, especially with twins
ALT: alanine aminotransferase; AST: aspartate aminotransferase
PATHOGENESIS 
The pathogenesis of AFLP still has not been fully 
elucidated. Though, studies showed association between 
defect in fetal mitochondrial fatty acid beta-oxidation and 
development of maternal AFLP, especially fetal defects 
in long-chain 3-hydroxyacyl-CoA dehydrogenase 
(LCHAD). Further, it is described in Figure 1.2, 20 
Long-chain 3-hydroxyacyl-CoA dehydrogenase 
deficiency is categorized within a group of disorders 
so-called as fetal fatty acid oxidation defects (FAOD). 
FAODs affect the mother because of physiologic 
metabolic changes during pregnancy that result in 
increased demand for free fatty acids (FFA). These 
FFA are also metabolized by the fetus and placenta for 
utilization in growth and development. The placenta 
contains lipoprotein lipase, fatty acid-binding proteins, 
carnitine transporters, and enzymes involved in fatty 
acid oxidation (FAO), such as LCHAD. These enzymes 
may contribute to overall metabolic stress on the 
mother. Due to fetus and placenta share a uniform 
genotype, the placenta is similarly unable to proceed 
with normal metabolic pathways if FAO fails in the 
fetus and the intermediate products of metabolism may 
accumulate in the placenta and the maternal blood, 
creating toxic effects in the mother.2-3, 20 
Toxic metabolic intermediates build up in maternal 
hepatocytes. Lipotoxicity, due to the accumulation of 
fatty acids and their metabolites in the maternal blood, 
causes increased reactive oxygen species (ROS). 
It has deleterious effects on hepatocytes, including 
activation of inflammatory pathways and cellular 
necrosis, leading to acute maternal hepatic failure, 
which may manifest as AFLP. Several factors appear 
to contribute to the fetal-maternal interaction. First, 
the heterozygosity of the mother for an mitochondrial 
trifunctional protein (MTP) defect reduces her capacity 
to oxidize long chain fatty acids. Second, third trimester 
is accompanied by changes in metabolism, an increased 
lipolysis, and a reduction in mitochondrial FAO, all 
increase the susceptibility of the mother carrying a 
fetus with LCHAD deficiency.2-3, 20
DIAGNOSIS
Acute fatty liver of pregnancy resembles symptoms 
that are unique to pregnancy. The onset is usually 
between 30th and 38th week of gestation, though few 
were reported starting in the second trimester.20 It is 
more frequent in primiparous women and can return 
in subsequent pregnancies.20 The patients may reveal 
non-specific symptoms. The initial manifestations 
include headache, fatigue, nausea, and vomiting.13 
fatty acids. Second, third trimester is accompanied by changes in metabolism, an increased 
lipolysis, and a r duction in mitochondrial FAO, all increase the susceptibility of t
mother carrying a fetus with LCHAD deficiency.2-3, 20 
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Clinical manifestation may vary from abdominal pain, 
jaundice, hypoglycemia, hepatic encephalopathy, 
coagulopathy.13 Jaundice appears 1-2 weeks after the 
onset of symptoms.3 Polyuria and polydipsia are found 
in about 5% of cases, though the mechanism is not 
clear.22 Some patients may have a low-grade fever.14 
Concomitant preeclampsia is present in approximately 
one half of the patients.
Laboratory findings revealed anemia, leukocytosis, 
thrombocytopenia, elevated aminotransferases 
levels (from mild to 1000 IU/L, usually 300-500 
IU/L), elevated bilirubin (frequently > 5 mg/dL), 
increased alkaline phosphatase, increased uric acid, 
renal impairment, proteinuria, metabolic acidosis, 
hyperammonemia, and biochemical pancreatitis. 
Hypoglycemia may also be noted, which is uncommon in 
other pregnancy-related liver disorders. Hypoglycemia 
is a poor prognostic sign. Hemostatic changes include 
thrombocytopenia, prolonged prothrombin time, and 
reduced fibrinogen levels. Procoagulant deficiency 
and DIC is due to hepatic dysfunction which is found 
in AFLP. Profound hemostatic dysfunction commonly 
exacerbates obstetric hemorrhage. David BN et al 
reported that hemostatic dysfunction with AFLP 
persists 4-5 days postpartum.22-27
Imaging studies, include ultrasound, abdominal 
computed tomography (CT), or MRI, may be helpful 
in supporting the diagnosis of AFLP. Fatty liver may be 
detected in ultrasound showing increased echogenicity 
(bright liver) and a CT indicating decreased liver density. 
Qiang Wei et al reported that rate of positive AFLP 
diagnosis was 79.7% by ultrasound, and 85.3% by CT, 
with no significant difference between the two methods.23 
Liver biopsy is the gold standard for AFLP, though 
it is rarely necessary. It should be avoided in cases with 
bleeding tendencies. The hallmark histopathologic 
finding of AFLP is microvesicular fatty infiltration of 
hepatocytes involving the pericentral zone and sparing 
the periportal hepatocyte (Figure 2). Microvesicular 
steatosis is confirmed on a special stain called Oil-
red-O which must be done on fresh-frozen sections. 
Beside the fatty change, the histopathologic findings 
may also encompass giant mitochondria, lymphocytic 
infiltration, and lack of sinusoidal fibrin deposition. 
It is reported that intrahepatic cholestasis, including 
bile canalicular plugs and acute cholangitis was 
found in two-thirds of cases. Upper gastrointestinal 
hemorrhage due to coagulation abnormalities may be 
seen in some cases. In severe untreated cases, it may 
complicate progressively into hepatic failure with 
coma, hypoglycemia, hyperammonemia, renal failure, 
and severe coagulopathy, with hemorrhage leading to 
death of the mother and fetus.1-2, 18 
Figure 2. Liver biopsy of acute fatty liver of pregnancy1
The diagnosis of AFLP is made clinically based on 
compatible manifestation, laboratory, and imaging results. 
The Swansea criteria have been proposed as a clinically 
diagnostic tool for AFLP, with 100% sensitivity, 57% 
specificity, 85% positive predictive value, and 100% 
negative predictive value (Table 3). Based on this criteria, 
the AFLP is considered if at least 6 out of the 15 criteria 
are met. Shan Wang et al reported that the criteria without 
liver biopsy are good screening tools for AFLP diagnosis, 
and further it may be useful for assessing disease severity. 
This criteria is used in the absence of other diagnosis of 
liver dysfunction (HELLP syndrome, preeclampsia), 
which further makes application challenging if multiple 
conditions co-exist.2,28 
Table 3. Diagnostic criteria of acute fatty liver of pregnancy 
based on Swansea criteria2, 4
The criteria
Vomiting
Abdominal pain
Polydipsia/polyuria
Encephalopathy
Hyperbilirubinemia (bilirubin > 0.8 mg/dL)
Hypoglycemia (blood glucose < 72 mg/dL)
Elevated urea (> 960 mg/dL)
Leukocytosis (WBC > 11,000/
Ascites 
Bright liver on ultrasound scan
Elevated transaminases (ALT >42 U/L)
Elevated ammonia (> 66)
AKI or creatinine > 1.7 mg/dL
Coagulopathy or PT >14 s
Microvesicular steatosis on liver biopsy
WBC: white blood count; AKI: acute kidney injury; PT: prothrombin time
The differential diagnosis of AFLP encompass 
hemolysis, elevated liver enzymes, and low platelets 
(HELLP) syndrome, preeclampsia, and intrahepatic 
cholestasis of pregnancy. The clinical characteristics 
and findings of several liver disorders of pregnancy 
are shown in Table 4.
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MANAGEMENT
AFLP has been considered an obstetric emergency 
that can lead to multiple organ failure in a short time 
unless it is diagnosed promptly. As a disease of the last 
trimester of pregnancy, AFLP appears with intriguing 
features, including non-specific gastrointestinal 
symptoms that are easily overlooked or misdiagnosed. 
The management of AFLP encompasses three 
aspects, those are: (1) Early recognition and diagnosis. 
Defining appropriate screening guidelines for 
outpatient pregnant women could be life-saving. The 
34th week of gestation has been recommended for 
this screening context. Firstly, liver and coagulation 
function tests could be performed for any pregnant 
woman who complains of new-onset gastrointestinal 
symptoms (e.g. abdominal pain, nausea, and vomiting). 
Once abnormal results are found, further tests should 
be performed, including renal function tests, blood 
glucose, and abdominal ultrasound.13,29; (2) Aggressive 
maternal stabilization. Intensive care admission should 
be needed to perform it through adequate supportive 
therapy. The supportive therapy consists of: (a) Diet low 
in fat and protein, high in carbohydrates; (b) Correction 
of dehydration, electrolyte and acid-base imbalance; 
(c) The correction of concurrent coagulopathy with 
adequate blood products should be considered first. 
The transfusion of fresh frozen plasma, cryoprecipitate, 
or platelet concentrates in the presence of abnormal 
tests, such as PT, activated partial thromboplastin time 
(aPTT), or fibrinogen could prevent further bleeding 
complications. Prothrombin time improvement is the 
first sign of hepatic recovery.1,4,13,19,26; (3) Expeditious 
termination of the pregnancy is the cornerstone of 
AFLP management, with cesarean section being the 
preferred mode of delivery. When vaginal delivery 
cannot be obtained quickly, caesarian section should 
be performed. A meta-analysis and systematic review 
by Hong-Yan Wang et al. revealed that caesarian 
section is associated with better pregnancy outcomes. 
Further they emphasized that caesarian section is the 
safest method of delivery and should be recommended 
to reduce the risk of adverse pregnancy outcome 
in patients with AFLP. The selection in anesthesia 
modalities in patients with AFLP requiring cesarean 
section should be invidualized. GuoXia, Z et al. 
reported that general anesthesia with rapid-sequence 
induction may be the best choice for patients with 
severe coagulopathy. 1,4,13,30,31 
Liver transplantation is considered as a last measure, 
though it remains controversial. The fulminant liver 
failure due to AFLP is usually reversible, and patients 
may be expected to recover normal function in weeks. 
If liver function worsens, it may be a sign of concurrent 
sepsis or hypoxic-ischemic liver injury. Use of liver 
transplantation in AFLP has been reported for cases 
of worsening clinical status, such as encephalopathy 
and lactic acidosis, and persistent liver failure despite 
optimal medical treatment. Yet, there is no official 
Table 4. The comparison of clinical characteristics and findings of AFLP and its differential diagnosis
Characteristics & 
findings AFLP HELLP Preeclampsia ICP
Prevalence 0.005-0.010% 0.2-0.6% 5-7% 0.1-0.3%
Maternal age >20 years >25 years <20 years and >45 years Advanced maternal age
Parity Nulli-/multiparity,
multifetal pregnancy, 
pregnancies carrying a 
male fetus
Multiparity Nulli-/multiparity, 
multifetal pregnancy
Multiparity, multifetal 
pregnancy
Family history Occasionally No Often Often
Onset 3rd trimester or postpartum Late 2nd/3rd trimester or 
postpartum
Late 2nd/3rd trimester 3rd trimester
Symptoms Abdominal pain, vomiting, 
polydipsia/polyuria, 
encephalopathy
Abdominal pain, 
vomiting, proteinuria, 
headache, peripheral 
edema
Abdominal pain, 
hypertension, 
proteinuria, headache, 
blurred vision, peripheral 
edema
Pruritis, jaundice
Sign Ascites + No ascites No ascites Icteric, no ascites
Laboratory 
Thrombocytopenia 
Bilirubin
Hypoglycemia 
Aminotransferases
Uric acid
Hemolysis
Creatinine
Proteinuria 
+ ↓
<10 mg/dL
+
5-10x
↑ (80%)
-
↑
+↑
+ ↓
<5 mg/dL
-
1-100x
↑
↑
-
+↑
+ ↓
<5 mg/dL
-
1-100x
↑
+↑
↑
↑
+ ↓
<5 mg/dL
-
1-5x
-
-
-
-
Histopathology Microvesicular steatosis Fibrin deposition, 
hemorrhage, 
hepatocellular necrosis
Fibrin deposition, 
hemorrhage, 
hepatocellular necrosis
Hepatocellular bile and 
canalicular bile plugs, 
cholestasis
AFLP: acute fatty liver of pregnancy; HELLP: hemolysis, elevated liver enzymes, low platelets; ICP: intrahepatic cholestasis of pregnancy
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guidelines for determining when transplantation should 
be considered.2
PROGNOSIS
Most patients with AFLP improve in 1 to 4 
weeks postpartum though cholestatic phase with 
hyperbilirubinemia and elevated alkaline phosphatase 
still persist. They can get recovery in days or months 
with no signs of chronic liver disease. Studies reported 
that there is no recovery before delivery. The prognosis 
in these patients were determined by the severity of 
liver dysfunction (serum bilirubin and prothrombin 
time), serum creatinine, and delay in delivery.10,19,32
There are some complications related to AFLP, 
including acute liver failure (ALF), acute renal failure, 
DIC, infections, acute respiratory distress syndrome, 
and acute pancreatitis. Yan-Ping Z et al reported that 
PT (OR = 1.558; 95% CI: 1.248-1.946, p = 0.016) 
and INR (OR = 40.034; 95% CI: 2.517-636.693; p 
= 0.009) are risk factors for fatal complications in 
patients with AFLP. Further, they also reported that 
fibrin degradation products is associated with perinatal 
mortality.33
ALF is a common complication of AFLP. Recent 
studies reported that 20-52% subjects develop ALF. 
The pathologic changes in patients with ALF due to 
AFLP are reported as ‘of a reversible kind’, with the 
clinical course and histopathologic findings clearly 
lead to a functional failure –not a destructive form 
of hepatic insufficiency. Further, Hao-Feng X et al 
reported that patients with ALF due to AFLP do not 
need specific long-term follow-up after recovery from 
AFLP if their liver function tests have normalized and 
they remain well.33,34 
The morbidity of renal impairment in AFLP is 
39-72.0%, and incidence of AKI requiring renal 
replacement therapy is 32.0%. Hao-Feng et al reported 
that renal function completely recovered at discharge 
and 6-months follow-up, suggesting that the renal 
damage in AFLP patients is reversible.33,34 
Compared to other liver diseases in pregnancy, 
AFLP revealed poorer outcome on maternal mortality. 
The maternal mortality of AFLP in 2000s was 7-18% 
(vs. 0% for ICP vs. 1-25% for HELLP syndrome). 
Compared to AFLP in the 1980s, this number were 
decreasing due to greater recognition of AFLP, 
improving time-to-diagnosis and time-to-subsequent 
delivery scheme, and improvement of obstetric 
intensive care. In Indonesia, 12 of 18 patients with 
AFLP were died with the maternal sepsis as the 
common direct cause. The risk or maternal mortality 
was associated with multiple complications and 
the presence of hypertension. Further, several 
complications were direct consequences of liver 
failure.2, 7, 19 
Perinatal mortality is still challenging. Perinatal 
mortality is 9-23% (vs. 0.4-1.4% for ICP vs. 11% for 
HELLP syndrome) and remains high. It is due in part 
to maternal acidosis that has immediate detrimental 
effects on fetus. In Indonesia, the perinatal morbidity 
as the outcome of AFLP was 57.89% with all neonates 
were developing early onset sepsis. This high burden is 
related to late diagnosis and suboptimal maternal-fetal 
surveillance following admission.2, 7, 19
Many patients with AFLP do not become pregnant 
again due to the devastating effect of the illness and/
or hysterectomy. There is small but definite risk of 
recurrence during subsequent pregnancies. Further 
studies and long-term postpartum evaluation are 
highly needed to evaluate the need of screening and 
the recurrence of AFLP.
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